To

**Date: 07.11.2025**

The Manager
**BSE Limited**
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

**Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636)**

**Sub: Outcome of Board Meeting and other matters under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Oxygenta Pharmaceutical Limited,** at its Meeting held on Friday, 07th November, 2025, at 3:30 P.M. at the corporate office of the Company, considered and approved the following:

1. Un-audited Financial Results for the quarter and half-year ended 30.09.2025. **(Attached)**
2. Limited Review Report for the quarter and half-year ended 30.09.2025. **(Attached)**
3. Appointment of Mr. Prasad Reddy Battinapatla as Chief Financial Officer of the Company with effect from 07th November, 2025. **(Details as annexed as Annexure - A)**
4. Approval of Notice of Postal Ballot and Calendar of events for Postal Ballot.
5. Appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries as Scrutinisers to conduct the e-voting process through Postal Ballot.

The Meeting concluded at 5:50 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
**For Oxygenta Pharmaceutical Limited**

KUMKUM BAJAJ

Digitally signed by KUMKUM BAJAJ
Date: 2025.11.07 17:59:11 +05'30'

**Kumkum Bajaj**
**Company Secretary & Compliance Officer**

**Annexure – A**

**[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024]**

| S. No | Particulars | Mr. Prasad Reddy Battinapatla |
|---|---|---|
| 1 | **Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~** | Mr. Prasad Reddy Battinapatla is appointed as Chief Financial Officer (CFO) of the Company. |
| 2 | **Date of Appointment~~/ cessation (as applicable)~~ & term of Appointment** | with effect from 07.11.2025. |
| 3 | **Brief profile (in case of appointment)** | Mr. Prasad Reddy Battinapatla is a Chartered Accountant and holds a bachelor's degree in commerce from Sri Venkateswara University. He has also completed a course on leadership and digital innovation in finance conducted by the Indian School of Business and has approximately 15 years of experience in the finance and accounts sector. |
| 4 | **Disclosure of relationships between directors (in case of appointment of a director)** | Not Applicable. |

**Thanking you,**
**For Oxygenta Pharmaceutical Limited**

KUMKUM BAJAJ
Digitally signed by KUMKUM BAJAJ
Date: 2025.11.07 17:59:34 +05'30'

**Kumkum Bajaj**
**Company Secretary & Compliance Officer**

**OXYGENTA PHARMACEUTICAL LIMITED**

**CIN : L24110TG1990PLC012038**

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rupees in Lakhs except for EPS)

| S. No | | Particulars | QUARTER ENDED | | | HALF YEAR ENDED | | YEAR ENDED |
|---|---|---|---|---|---|---|---|---|
| | | | 30/09/2025 | 30/06/2025 | 30/09/2024 | 30/09/2025 | 30/09/2024 | 31-03-2025 |
| | | | (Unaudited ) | (Unaudited ) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | **Income from Operations** | | | | | | | |
| | (a) | Net Sales/Income from Operations (net of excise duty) | 1,430.23 | 1,513.47 | 1,400.52 | 2,943.69 | 2,662.60 | 10,929.86 |
| | (b) | Other Operating Income | (5.62) | 16.91 | 74.93 | 11.29 | 77.18 | 130.91 |
| | **Total income from operations (net)** | | 1,424.61 | 1,530.37 | 1,475.45 | 2,954.99 | 2,739.78 | 11,060.77 |
| 2 | | **Expenses** | | | | | | |
| | (a) | Cost of materials consumed | 1,696.51 | 1,565.88 | 793.67 | 3,262.39 | 1,859.45 | 10,023.06 |
| | (b) | Purchase of stock-in-trade | - | - | - | | - | - |
| | (c) | Changes in inventories of finished goods, work- in-progress and stock-in-trade | (452.80) | (70.34) | 290.39 | (523.14) | 224.49 | (376.06) |
| | (d) | Direct Manufacturing Expenses | 379.34 | 386.18 | 255.56 | 765.52 | 450.78 | 1,116.09 |
| | (e) | Employee benefit expense | 203.47 | 200.19 | 139.50 | 403.66 | 287.68 | 684.70 |
| | (f) | Finance Costs | 94.96 | 62.84 | 69.09 | 157.80 | 109.77 | 361.42 |
| | (g) | Depreciation and amortisation expense | 85.71 | 84.73 | 65.99 | 170.44 | 130.93 | 178.16 |
| | (h) | Other expenses | 61.20 | 114.51 | 138.59 | 175.72 | 235.71 | 476.51 |
| | (i) | Prior Period Expense | | | | | - | 5.02 |
| | **Total expenses** | | 2,068.39 | 2,343.99 | 1,752.78 | 4,412.39 | 3,298.81 | 12,468.91 |
| 3 | **Profit from operations before other income and exceptional items (1-2)** | | (643.78) | (813.62) | (277.33) | (1,457.40) | (559.03) | (1,408.14) |
| 4 | **Other income** | | - | - | - | - | - | |
| 5 | **Profit from ordinary activities before exceptional items (3+4)** | | (643.78) | (813.62) | (277.33) | (1,457.40) | (559.03) | (1,408.14) |
| 6 | **Exceptional (expenses)/income** | | | (1.18) | - | (1.39) | - | (27.00) |
| 7 | **Profit / (Loss) from ordinary activities before tax (7+ 8)** | | (643.78) | (814.80) | (277.33) | (1,458.79) | (559.03) | (1,435.14) |
| 8 | **Tax (expense)/credit** | | - | - | - | | - | - |
| | **Current Tax** | | | | | | | |
| | **Deferred Tax** | | (150.74) | (204.19) | 8.05 | (354.93) | (137.32) | (421.45) |
| | **Prior period Income tax adjustment** | | | | | | | 15.96 |
| 9 | **Net Profit / (Loss) from ordinary activities after tax** | | (493.04) | (610.61) | (285.38) | (1,103.87) | (421.71) | (1,029.65) |
| 10 | **Extraordinary items (net of tax expense )** | | - | - | - | - | - | - |
| 11 | **Net Profit / (Loss) for the period (11+ 12)** | | (493.04) | (610.61) | (285.38) | (1,103.87) | (421.71) | (1,029.65) |
| 12 | **Other Comprehensive Income** | | - | - | - | | - | 10.73 |
| 13 | **Total Comprehensive Income** | | (493.04) | (610.61) | (285.38) | (1,103.87) | (421.71) | (1,040.38) |
| 14 | **Share of Profit/(loss) of associates** | | - | - | - | - | - | - |
| 15 | **Minority interest** | | - | - | - | - | - | - |
| 16 | **Paid-up equity share capital** | | 3,698.35 | 3,698.35 | 3,548.35 | 3,698.35 | 3,548.35 | 3,698.35 |
| | **(face value Rs. 10/- )** | | | | | | | |
| 17.i | **Earnings per share (before extraordinary items)** | | | | | | | |
| | **( of Rs.10/- each ) (not annualised):** | | | | | | | |
| | **(a) Basic** | | (1.33) | (1.65) | (0.81) | (2.98) | (1.20) | (2.86) |
| | **(b) Diluted** | | (1.33) | (1.65) | (0.78) | (2.98) | (1.15) | (2.86) |
| 17.ii | **Earnings per share (after extraordinary items)** | | | | | | | |
| | **( of Rs.10/- each ) (not annualised):** | | | | | | | |
| | **(a) Basic** | | (1.33) | (1.65) | (0.81) | (2.98) | (1.20) | (2.86) |
| | **(b) Diluted** | | (1.33) | (1.65) | (0.78) | (2.98) | (1.15) | (2.86) |

**NOTES:**

1 The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 7th November, 2025 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad

2 The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

3 The financial results of the company have been prepared in accordance with Indian Accouting Standards (Ind AS) notified under the companies (Indian Accouting standards) Rules, 2015 as amended by the companies (Indian Accouting standards) (Amendment) rules,2016.

4 The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made

5 Total Turnover for the current quarter reported Rs 1430.23 Lakhs compared to Rs.1400.52 for the corresponding quarter of the previous year.

6 The Loss before tax for the current quarter is Rs.643.78 Lakhs compared to Loss Before tax of Rs.277.33 Lakhs for the corresponding quarter of the previous year.

7 Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparision.

8 The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting.
Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.

OXYGENTA PHARMACEUTICAL LIMITED Hyderabad

For and on behalf of the Board of Directors
**OXYGENTA PHARMACEUTICAL LIMITED**

**BALASUBBA REDDY MAMILLA**

Whole Time Director

DIN :01998852

Date: 07/11/2025
Place; Hyderabad

**OXYGENTA PHARMACEUTICAL LIMITED**
**CIN: L24110TG1990PLC012038**

**Un Audited Statement of Assets and Liabilties as at September 30, 2025**

(All amounts are in INR Lakhs, except for share data and where otherwise stated)

| Particulars | Note | As at September 30, 2025 Un Audited | As at March 31, 2025 Audited |
|---|---|---|---|
| **I. ASSETS** | | | |
| **Non-current assets** | | | |
| (a) Property, plant and equipment | 3 | 4,129.89 | 3,683.04 |
| (b) Other intangible assets | | - | - |
| (c) Capital work in progress | 3 | 25.20 | 23.43 |
| (d) Goodwill | | - | - |
| (e) Right-of-use assets | | - | - |
| (f) Financial assets | | - | - |
| (i) Investments | 4A | 4.94 | 4.94 |
| (ii) Loans | 4B | - | - |
| (iii) Trade Receivables | 8 | 421.17 | 108.30 |
| (iv) Other financial assets | 5 | 250.19 | 68.10 |
| (g) Deferred tax assets (net) | 6 | 1,653.27 | 1,298.34 |
| (h) Other non-current assets | | - | - |
| **Total non-current assets** | | **6,484.65** | **5,186.15** |
| **Current assets** | | | |
| Inventories | 7 | 2,708.99 | 2,051.30 |
| (a) Financial assets | | | |
| (i) Trade receivables | 8 | 1,572.82 | 509.80 |
| (ii) Cash and cash equivalents | 9 | 113.86 | 0.17 |
| (iii) Bank balances other than Cash and cash equivalents | | 10.13 | 12.01 |
| (iv) Other financial assets | | - | - |
| (b) Other current assets | 10 | 786.07 | 521.01 |
| **Total Current Assets** | | **5,191.87** | **3,094.30** |
| **TOTAL ASSETS** | | **11,676.53** | **8,280.45** |
| **II. EQUITY AND LIABILITIES** | | | |
| **Equity** | | | |
| (a) Equity share capital | 11 | 3,698.35 | 3,698.35 |
| (b) Other equity | 12 | (7,366.27) | (6,262.40) |
| **Total equity** | | **(3,667.92)** | **(2,564.05)** |
| **Non-current liabilities** | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13A | 2,707.35 | 2,152.24 |
| (ii) Lease liabilities | | | - |
| (b) Provisions | 14A | 134.35 | 107.51 |
| (c)Deferred Tax Liabilities | | | |
| **Total non-current Liabilities** | | **2,841.70** | **2,259.75** |
| **Current liabilities** | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13B | 4,575.55 | 4,071.00 |
| (ii) Lease liabilities | | | |
| (iii) Trade payables | 15 | | |
| - Total outstanding dues of micro and small enterprises | | 498.95 | 648.26 |
| - Total outstanding dues of creditors other than micro and small enterprises | | 7,205.30 | 2,331.13 |
| (iv) Other financial liabilities | | - | - |
| (b) Other current liabilities | 16 | 208.86 | 1,511.34 |
| (c) Provisions | 14B | 14.09 | 23.01 |
| **Total current liabilities** | | **12,502.75** | **8,584.74** |
| **TOTAL EQUITY AND LIABILITIES** | | **11,676.53** | **8,280.44** |

The accompanying notes form an integral part of the financial statements

For and on behalf of the Board of Directors of
**OXYGENTA PHARMACEUTICAL LIMITED**
CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED Hyderabad

**BALASUBBA REDDY MAMILLA**
Whole Time Director
DIN :01998852

**OXYGENTA PHARMACEUTICAL LIMITED**
CIN: L24110TG1990PLC012038
Un Audited Statement of Cash Flows for the Period ended September 30, 2025

(All amounts are in INR Lakhs, except for share data and where otherwise stated)

| | Particulars | For the Period ended September 30, 2025 Un Audited | For the Year ended March 31, 2025 Audited |
|---|---|---|---|
| I | **CASH FLOW FROM OPERATING ACTIVITIES** | | |
| | Profit before tax | (1,458.79) | (1,435.14) |
| | Adjustments for: | | |
| | Depreciation and amortisation expenses | 170.44 | 361.42 |
| | Finance costs | 157.80 | 178.16 |
| | Interest income | (2.70) | (2.25) |
| | Other Income | (8.50) | (128.66) |
| | Provision for bad and doubtful debts | - | 77.23 |
| | Forex Loss/ (gain) | (0.09) | - |
| | Provision for gratuity and leave encashment | 28.55 | 42.60 |
| | **Operating profit before working capital changes** | **(1,113.30)** | **(906.63)** |
| | Working capital changes: | | |
| | (Increase)/Decrease in Trade receivables | (1,375.89) | 117.95 |
| | (Increase) in Other financial assets | (182.08) | 26.45 |
| | Decrease in Other current assets | (265.06) | (228.21) |
| | (Increase)/Decrease in Inventories | (657.69) | (679.65) |
| | (Increase)/Decrease in Other non current assets | - | - |
| | (Decrease) in Trade payables | 4,724.87 | 690.65 |
| | Increase/(Decrease) in Other current liabilities | (1,293.98) | 1,260.93 |
| | Increase/(Decrease) in Other financial liabilities | - | - |
| | Increase/(Decrease) in Provisions | (10.53) | (5.25) |
| | **Cash generated from operations** | **(173.67)** | **276.24** |
| | Income taxes received/(paid) | - | (15.96) |
| | **Net cash generated from operating activities** | **(173.67)** | **260.29** |
| II | **CASH FLOW FROM INVESTING ACTIVITIES** | | |
| | Payment for property plant and equipment and CWIP | (619.06) | (1,139.15) |
| | Proceeds from sale of property plant and equipment and CWIP | - | 12.00 |
| | Interest received on fixed deposits | 2.70 | 2.25 |
| | Movement in other bank balances and bank deposits with maturity period of more than three months | - | - |
| | **Net cash generated from/(used in) investing activities** | **(616.37)** | **(1,124.91)** |
| III | **CASH FLOW FROM FINANCING ACTIVITIES** | | |
| | Interest paid | (157.80) | (178.16) |
| | Repayment of lease liabilities | - | - |
| | Proceeds from issuing shares | - | 545.00 |
| | Proceeds from issuing other equity instruments | - | - |
| | Increase/(decrease) from Long term borrowings | 555.10 | (2,747.92) |
| | Increase/(decrease) from Short term borrowings | 504.55 | 3,247.80 |
| | **Net cash generated from/(used in) financing activities** | **901.85** | **866.71** |
| IV | **Net increase in cash and cash equivalents** | 111.81 | 2.10 |
| | Cash and cash equivalents at the beginning of the year | 12.18 | 10.08 |
| | **Cash and cash equivalents at the end of the year** | **123.99** | **12.18** |

The accompanying notes form an integral part of the financial statements

For and on behalf of the Board of Directors of
**OXYGENTA PHARMACEUTICAL LIMITED**
CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED Hyderabad

**BALASUBBA REDDY MAMILLA**
Whole Time Director
DIN :01998852

**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended and Six months ended September 30, 2025 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")

2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A.M REDDY & D.R REDDY**

Chartered Accountants

Firms Registration No: 009068S

D. Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: **25209211BMJBQN5520**

Place: Hyderabad

Date: November 07, 2025

A.M. Reddy & D.R. Reddy Hyderabad Chartered Accountants

H.O #14/186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 |Phone No: 08554-231666
B.O H.No 3-6-640/1/C, Fourth Floor, Street No 9, Himayat Nagar , Hyderabad 500 029 | Phone No : 040-40077393
Mobile No: 9848032382 Email ID: rkreddy1999#yahoo.com